{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:08:37Z","timestamp":1791090517272,"version":"4.1.0"},"reference-count":149,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research on Neuroimmunological Disorders"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Multiple sclerosis is an important neurological disease affecting millions of young patients globally. It is encouraging that more than ten disease-modifying drugs became available for use in the past two decades. These disease-modifying therapies (DMTs) have different levels of efficacy, routes of administration, adverse effect profiles and concerns for pregnancy. Much knowledge and caution are needed for their appropriate use in MS patients who are heterogeneous in clinical features and severity, lesion load on magnetic resonance imaging and response to DMT. We aim for an updated review of the concept of personalization in the use of DMT for relapsing MS patients. Shared decision making with consideration for the preference and expectation of patients who understand the potential efficacy\/benefits and risks of DMT is advocated.<\/jats:p>","DOI":"10.3390\/pharmaceutics16010120","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T07:41:28Z","timestamp":1705477288000},"page":"120","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-2360","authenticated-orcid":false,"given":"Chi-Yan","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 405B, 4\/F, Professorial Block, 102 Pokfulam Road, Hong Kong"},{"name":"Neuroimmunology and Neuroinflammation Research Laboratory, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koon-Ho","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 405B, 4\/F, Professorial Block, 102 Pokfulam Road, Hong Kong"},{"name":"Neuroimmunology and Neuroinflammation Research Laboratory, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong"},{"name":"Research Center of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple Sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: Implication for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis- the plaques and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"M\u00fcller, J., Cagol, A., Lorscheider, J., Tsagkas, C., Benkert, P., Yaldizli, \u00d6., Kuhle, J., Derfuss, T., Sormani, M.P., and Thompson, A. (2023). Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review. JAMA Neurol., Online ahead of print.","DOI":"10.1001\/jamaneurol.2023.3331"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Saji","year":"2018","journal-title":"Brain"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis","volume":"128","author":"Kutzelnigg","year":"2005","journal-title":"Brain"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tig.2017.09.004","article-title":"The genetics of multiple sclerosis from 0 to 200 in 50 years","volume":"33","author":"Baranzini","year":"2017","journal-title":"Trends Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cell.2020.09.054","article-title":"HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis","volume":"183","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"International Multiple Sclerosis Genetics Consortium (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet., 45, 1353\u20131360.","DOI":"10.1038\/ng.2770"},{"key":"ref_14","unstructured":"International Multiple Sclerosis Genetics Consortium (2019). Multiple sclerosis genomic map implicates peripheral immune cells and microglia susceptibility. Science, 365, eaav7188."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Pri."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein-Barr virus in multiple sclerosis: Theory and emerging immunotherapies","volume":"26","author":"Pender","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: Interactions, checks, and balances","volume":"20","author":"Li","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","article-title":"Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis","volume":"15","author":"Rotstein","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm1651","article-title":"Human Th17 lymphocytes promote blood-brain-barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awy069","article-title":"T helper 17.1 cells associate with multiple sclerosis disease activity: Perspectives for early intervention","volume":"141","author":"Janssen","year":"2018","journal-title":"Brain"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2567.2007.02690.x","article-title":"Compromised CD4+CD25high regulatory T cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level","volume":"123","author":"Venken","year":"2008","journal-title":"Immunology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"a029041","DOI":"10.1101\/cshperspect.a029041","article-title":"Regulatory T cells from discovery to autoimmunity","volume":"14","author":"Kitz","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/brain\/awq354","article-title":"CD161highCD8+T cells bear potential in multiple sclerosis","volume":"134","author":"Annibali","year":"2011","journal-title":"Brain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/awz017","article-title":"Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis","volume":"142","author":"Mexhitaj","year":"2019","journal-title":"Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-Cell Depletion with Rituximab in Relapsing\u2013Remitting Multiple Sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B cell cytokines responses a trigger of T cell-mediated disease in MS?","volume":"67","author":"Fawaz","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing autoreactive CD4+ T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.4049\/jimmunol.1502448","article-title":"Age-associated B cells with proinflammatory characteristics are expanding in a proportion of multiple sclerosis patients","volume":"197","author":"Claes","year":"2016","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ana.25508","article-title":"Induction of brain-inflitrating T-bet-expressing B cells in multiple sclerosis","volume":"86","author":"Rijvers","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41582-019-0253-6","article-title":"When encephalitogenic T cells collaborate with microglia in multiple sclerosis","volume":"15","author":"Dong","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41582-019-0184-2","article-title":"The pro-remyelination properties of microglia in the central nervous system","volume":"15","author":"Lloyd","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2023.03.008","article-title":"Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting","volume":"186","author":"Charabati","year":"2023","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104068","DOI":"10.1016\/j.lpm.2021.104068","article-title":"Update on treatment in multiple sclerosis","volume":"50","author":"IIaria","year":"2021","journal-title":"Presse Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing remitting multiple sclerosis (ADVANCE): A randomized phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_45","first-page":"S17","article-title":"Interferon \u03b2 mechanisms of action in multiple sclerosis","volume":"74","author":"Marks","year":"2010","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.clinthera.2009.08.003","article-title":"Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: Design and lessons from a 16-year observational study","volume":"31","author":"Elbers","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0b013e3181e240d0","article-title":"Cross-sectional study assessing long-term safety of interferon-\u03b21b for relapsing remitting MS","volume":"74","author":"Reder","year":"2010","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","article-title":"Survival in MS: A randomized cohort study of 21 years after the start of the pivotal IFN\u03b21b trial","volume":"78","author":"Goodin","year":"2012","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"PRISMS Study Group (1998). Randomized double-blind placebo-controlled study of interferon \u03b21-a in relapsing\/remitting multiple sclerosis PRISM (Prevention of Relapses and Disability by Interferon \u03b2-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet, 352, 1498\u20131504.","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"PRISMS Study Group and the University of British Columbia (2001). PRISM-4: Long-term efficacy of interferon-\u03b21a in relapsing MS. Neurology, 56, 1628\u20131636.","DOI":"10.1212\/WNL.56.12.1628"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1212\/01.wnl.0000237994.95410.ce","article-title":"Long-term subcutaneous interferon \u03b2-1a therapy in patients with relapsing-remitting MS","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285610391693","article-title":"Impact of exposure to interferon \u03b2-1a on outcomes in patients with relapsing remitting multiple sclerosis. Exploratory analyses from the PRISMS long-term follow-up study","volume":"4","author":"Uitdehagg","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/1352458514557986","article-title":"Peginterferon \u03b2-1a in multiple sclerosis: 2-year results from ADVANCE","volume":"21","author":"Kieseier","year":"2015","journal-title":"Mult. Scler. J."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Arnold, D.L., Calabresi, P.A., Kieseier, B.C., Sheikh, S.I., Deykin, A., Zhu, Y., Liu, S., You, X., Sperling, B., and Hung, S. (2014). Effect of peginterferon \u03b2-1a on MRI measures and achieving no evidence of disease activity: Results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol., 14.","DOI":"10.1186\/s12883-014-0240-x"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1352458510388823","article-title":"High-dose frequency \u03b2-interferon increase the risk of liver test abnormalities in multiple sclerosis: A longitudinal study","volume":"17","author":"Chan","year":"2010","journal-title":"Mult. Scler. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.msard.2013.11.005","article-title":"Short-term and long-term safety and tolerability of interferon \u03b2-1b in multiple sclerosis","volume":"3","author":"Reder","year":"2014","journal-title":"Mult. Scler. J. Relat. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/1352458516634872","article-title":"Interferon-beta exposure during first trimester is safe in women with multiple sclerosis- a prospective cohort study from the German multiple sclerosis and pregnancy registry","volume":"22","author":"Thiel","year":"2016","journal-title":"Mult. Scler. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ene.12797","article-title":"An overview of pregnancy-related issues in patients with multiple sclerosis","volume":"22","author":"Pozzilli","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11940-021-00666-4","article-title":"Treatment of women with multiple sclerosis planning pregnancy","volume":"23","author":"Krysko","year":"2021","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Jakimovski, D., Kolb, C., Ramanathan, M., Zivadinov, R., and Weinstock-Guttman, B. (2018). Interferon \u03b2 for Multiple Sclerosis, Cold Spring Harbor Laboratory Press.","DOI":"10.1101\/cshperspect.a032003"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/11588120-000000000-00000","article-title":"Glatiramer Acetate in the Treatment of Multiple Sclerosis","volume":"25","author":"Lalive","year":"2011","journal-title":"CNS Drugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","article-title":"European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging\u2013measured disease activity and burden in patients with relapsing multiple sclerosis. European\/Canadian Glatiramer Acetate Study Group","volume":"49","author":"Comi","year":"2001","journal-title":"Ann. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing\u2013remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458512469695","article-title":"Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome","volume":"19","author":"Comi","year":"2013","journal-title":"Mult. Scler. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7224\/1537-2073.2016-079","article-title":"Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database","volume":"20","author":"Neudorfer","year":"2018","journal-title":"Int. J. MS Care"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanisms of action in multiple sclerosis","volume":"74","author":"Pachner","year":"2014","journal-title":"Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing remitting multiple sclerosis","volume":"365","author":"Wolinsky","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing remitting multiple sclerosis (TOWER): A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Vermersch, P., Gold, R., Meca-Lallana, J., Thangavelu, K., Truffinet, P., Mandel, M., Cavalier, S., and Coyle, P. (2018, January 21\u201327). Treatment satisfaction with teriflunomide in patients switching from a prior disease-modifying therapy: Results from the Phase 3 TENERE extension and Phase 4 Teri-PRO clinical trials. Proceedings of the 70th AN of AAN 2018, Los Angeles, CA, USA.","DOI":"10.1212\/WNL.90.15_supplement.P6.396"},{"key":"ref_72","unstructured":"Kappos, L., Burcklen, M., Freedman, M.S., Fox, R., Havrdova, E.K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., and Pozzilli, C. (2019, January 11\u201313). Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing remitting multiple sclerosis: Results of the randomized, active-controlled, double-blind, parallel-group Phase 3 OPTIMUM study. Proceedings of the 35th Congress of ECTRIMS 2019, Stockholm, Sweden."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1212\/NXI.0000000000000390","article-title":"Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA","volume":"4","author":"Radue","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"17562864209970754","DOI":"10.1177\/1756286420970754","article-title":"Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS","volume":"13","author":"Zivadinov","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_76","first-page":"387","article-title":"An updated review of teriflunomide\u2019s use in multiple sclerosis. Neurodegener","volume":"11","author":"Miller","year":"2021","journal-title":"Dis. Manag"},{"key":"ref_77","unstructured":"(2019). Aubagio (Teriflunomide) Prescribing Information, Genzyme Corp."},{"key":"ref_78","unstructured":"FDA (2012). Aubagio [Package Insert], Genzyme Corporation."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458520949158","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","volume":"28","author":"Jordan","year":"2022","journal-title":"Mult. Scler. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"175628642091500","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","article-title":"Pregnancy and multiple sclerosis: An update","volume":"33","author":"Varyte","year":"2021","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing remitting multiple sclerosis (FREEDOM II): A double-blind randomized, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_88","first-page":"1","article-title":"Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML","volume":"8","author":"Oechtering","year":"2021","journal-title":"Neurology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomized, phase 3","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): An adaptive, dose-ranging, randomized, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: First approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicenter, randomized, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicenter, randomized, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1474-4422(19)30391-6","article-title":"Advances in oral immunomodulating therapies in relapsing multiple sclerosis","volume":"19","author":"Derfuss","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to Treat Relapsing Forms of Multiple Sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","article-title":"No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine","volume":"2","author":"Pakpoor","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1b for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_102","unstructured":"(2022). TYSABRI (Natalizumab) [Package Insert] 10\/2022 MEDICA Document Number: MH-0133, Biogen, Inc."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: Results from the AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorenson","year":"2014","journal-title":"J. Neurol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon-1a at 5-year follow-up of CAMMS223 Clinical Trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1000152","DOI":"10.4172\/2155-9899.1000152","article-title":"Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis","volume":"4","author":"Freedman","year":"2013","journal-title":"J. Clin. Cell. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458518796675","article-title":"Infection risk with alemtuzumab decreases over time: Pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study","volume":"25","author":"Wray","year":"2019","journal-title":"Mult. Scler. J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","article-title":"Immune competence after alemtuzumab treatment of multiple sclerosis","volume":"81","author":"McCarthy","year":"2013","journal-title":"Neurology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bjh.15132","article-title":"New insights in Type I and II CD 20 antibody mechanisms-of-action with a panel of novel CD 20 antibodies","volume":"180","author":"Meyer","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: Current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J. Neurol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis\u2014From targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_121","first-page":"e1805","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis","volume":"90","author":"Grove","year":"2018","journal-title":"Neurology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients","volume":"87","author":"Alping","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1352458518768433","article-title":"Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis","volume":"24","author":"Lorscheider","year":"2018","journal-title":"Mult. Scler. J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1756286420982134","DOI":"10.1177\/1756286420982134","article-title":"Efficacy and safety of alemtuzumab over 6 years: Final results of the 4-year CARE-MS extension trial","volume":"14","author":"Coles","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_129","first-page":"e1041","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study","volume":"95","author":"Burton","year":"2020","journal-title":"Neurology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"MSBase Study Group. Association of intiail disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"17562864211019574","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2012.12.001","article-title":"Editor\u2019s welcome and a working definition for a multiple sclerosis cure","volume":"2","author":"Banwell","year":"2013","journal-title":"Mult. Scler. J. Relat. Disord."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/1352458516650736","article-title":"Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies","volume":"22","author":"Baroncini","year":"2016","journal-title":"Mult. Scler. J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/ene.13936","article-title":"Natalizumab, rituximab, and fingolimod as escalation therapy in multiple sclerosis","volume":"26","author":"Boremalm","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/jnnp-2016-313760","article-title":"Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study","volume":"87","author":"Kister","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40266-019-00741-1","article-title":"Informing medication discontinuation decisions among older adults with relapsing-onset multiple sclerosis","volume":"37","author":"Schwehr","year":"2020","journal-title":"Drugs Aging"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1756285616631897","article-title":"Management of women with multiple sclerosis through pregnancy and after childbirth","volume":"9","author":"Coyle","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Pregnancy in Multiple Sclerosis Group. Rate of pregnancy-related relapse in multiple sclerosis","volume":"339","author":"Confavreux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"102241","DOI":"10.1016\/j.msard.2020.102241","article-title":"Change in pregnancy-associated multiple sclerosis relapse rates over time: A meta-analysis","volume":"44","author":"Dobson","year":"2020","journal-title":"Mult. Scler. J. Relat. Disord."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/1352458517731913","article-title":"Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis","volume":"24","author":"Meinl","year":"2018","journal-title":"Mult. Scler. J. Relat. Disord."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000377","article-title":"Dramatic rebounds of MS during pregnancy following fingolimod withdrawal","volume":"4","author":"Novi","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000566","article-title":"Different MRI patterns in MS worsening after stopping fingolimod","volume":"6","author":"Lapucci","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1007\/s00415-012-6553-z","article-title":"Breastfeeding and multiple sclerosis relapses: A meta-analysis","volume":"259","author":"Pakpoor","year":"2012","journal-title":"J. Neurol."},{"key":"ref_149","first-page":"6527458","article-title":"Management of multiple sclerosis in the breastfeeding mother","volume":"2016","author":"Almas","year":"2016","journal-title":"Mult. Scler. J. Int."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/1\/120\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:48:50Z","timestamp":1760104130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/1\/120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["pharmaceutics16010120"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16010120","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]}}}